INNOCARE
诺诚健华

InnoCare Pharma Limited
諾誠健華醫藥有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 9969)

VOLUNTARY ANNOUNCEMENT

SOFICITINIB (ICP-332) PHASE III REGISTRATIONAL TRIAL IN MODERATE-TO-SEVERE ATOPIC DERMATITIS SUCCESSFULLY MET ITS PRIMARY ENDPOINT

This announcement is made by InnoCare Pharma Limited (the "**Company**") on a voluntary basis to inform shareholders and potential investors of the Company's latest business developments.

The board of directors of the Company (the "**Board**") is pleased to announce that the Phase III registrational clinical trial of soficitinib (ICP-332), the Company's internally discovered and developed next-generation oral tyrosine kinase 2 (TYK2) inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (the "**AD**"), has successfully met its primary endpoint.

The Phase III study is a randomized, double-blind, placebo-controlled, multicenter registrational clinical trial designed to evaluate the efficacy, safety and tolerability of soficitinib (ICP-332) in adult patients with moderate-to-severe atopic dermatitis.

The study demonstrated that soficitinib (ICP-332) achieved the primary endpoint with statistical significance and clinically meaningful improvement. In addition, multiple secondary endpoints were successfully met, demonstrating a consistent treatment effect across efficacy measures. Detailed efficacy and safety data from the study will be presented at upcoming international scientific congresses and submitted for publication in peer-reviewed medical journals.

The safety profile of soficitinib (ICP-332) was consistent with previous clinical studies, and no new safety signals were identified.

Atopic dermatitis is a chronic, relapsing inflammatory skin disease characterized by intense pruritus, eczema and substantial impairment in patients' quality of life. Although treatment options have expanded in recent years, there remains a need for effective, well-tolerated oral therapies that provide sustained disease control.

Soficitinib (ICP-332) is a next-generation, highly selective oral TYK2 inhibitor discovered and developed by the Company. TYK2 is a member of the JAK family and plays a critical role in transducing signals downstream of IL-12/IL-23 family interleukin receptors as well as type I interferon receptor. These cytokine/receptor pathways regulate the activity of T helper 17, T helper 1, B and myeloid cells, which are critical in the pathobiology of multiple autoimmune and chronic inflammatory diseases including psoriasis, inflammatory bowel disease, lupus, AD, etc. Soficitinib (ICP-332) was designed to be a potent and selective TYK2 inhibitor with 400-fold selectivity against JAK2 with the aim of minimizing adverse events associated with nonselective JAK inhibitors. Thus, by selective inhibition of TYK2, soficitinib (ICP-332) has the potential to provide meaningful therapeutic benefit for multiple autoimmune diseases with a potentially favorable safety profile. As of the date of this announcement, soficitinib (ICP-332) is being evaluated across five autoimmune indications, including AD, vitiligo, prurigo nodularis, chronic spontaneous urticaria and psoriasis, with multiple clinical data readouts expected.

The Company will continue to complete the ongoing Phase III study, including the long-term safety follow-up, and plans to advance the regulatory filing process for soficitinib (ICP-332) for the treatment of moderate-to-severe atopic dermatitis following the completion of the study.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize soficitinib (ICP-332) for the treatment of AD successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 15 July 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.